LOWERING THE BINDING STRENGTH OF ANTI-CD19 CAR-T CELLS CAN REDUCE TOXICITY BUT AT THE COST OF IN VIVO ANTI-TUMOR EFFICACY

Doetsch S, Warmuth L, D'Ippolito E, Honold B, Trebo M, Manlik W, Graml F, Stengl A, Schuetz J, Schober K, Schmidt G, Wanisch A, Casucci M, Riddell S, Busch D (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Human Gene Therapy Mary Ann Liebert

Publisher: MARY ANN LIEBERT, INC

City/Town: NEW ROCHELLE

Pages Range: A13-A14

Conference Proceedings Title: HUMAN GENE THERAPY

Authors with CRIS profile

Kilian Schober Institute of Microbiology – Clinical Microbiology, Immunology and Hygiene

Involved external institutions

Università Vita-Salute San Raffaele (UniSR) IT Italy (IT) University of Washington US United States (USA) (US) Technische Universität München (TUM) DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE)

How to cite

APA:

Doetsch, S., Warmuth, L., D'Ippolito, E., Honold, B., Trebo, M., Manlik, W.,... Busch, D. (2022). LOWERING THE BINDING STRENGTH OF ANTI-CD19 CAR-T CELLS CAN REDUCE TOXICITY BUT AT THE COST OF IN VIVO ANTI-TUMOR EFFICACY. In HUMAN GENE THERAPY (pp. A13-A14). NEW ROCHELLE: MARY ANN LIEBERT, INC.

MLA:

Doetsch, S., et al. "LOWERING THE BINDING STRENGTH OF ANTI-CD19 CAR-T CELLS CAN REDUCE TOXICITY BUT AT THE COST OF IN VIVO ANTI-TUMOR EFFICACY." Proceedings of the HUMAN GENE THERAPY NEW ROCHELLE: MARY ANN LIEBERT, INC, 2022. A13-A14.

BibTeX: Download